Arrowhead Pharmaceuticals ARWR Stock
Arrowhead Pharmaceuticals Price Chart
Arrowhead Pharmaceuticals ARWR Financial and Trading Overview
| Arrowhead Pharmaceuticals stock price | 61.48 USD |
| Previous Close | 64.19 USD |
| Open | 64.76 USD |
| Bid | 58.43 USD x 200 |
| Ask | 67.73 USD x 200 |
| Day's Range | 62.22 - 64.76 USD |
| 52 Week Range | 34.61 - 95.49 USD |
| Volume | 2.25M USD |
| Avg. Volume | 1.9M USD |
| Market Cap | 8.78B USD |
| Beta (5Y Monthly) | 1.303 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.28 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.23 USD |
ARWR Valuation Measures
| Enterprise Value | 8.59B USD |
| Trailing P/E | N/A |
| Forward P/E | -12.644468 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.118 |
| Price/Book (mrq) | 18.905396 |
| Enterprise Value/Revenue | 12.829 |
| Enterprise Value/EBITDA | -42.81 |
Trading Information
Arrowhead Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.303 |
| 52-Week Change | 75.67% |
| S&P500 52-Week Change | 14.57% |
| 52 Week High | 95.49 USD |
| 52 Week Low | 34.61 USD |
| 50-Day Moving Average | 80.81 USD |
| 200-Day Moving Average | 72.49 USD |
ARWR Share Statistics
| Avg. Volume (3 month) | 1.9M USD |
| Avg. Daily Volume (10-Days) | 2.05M USD |
| Shares Outstanding | 140.86M |
| Float | 122.45M |
| Short Ratio | 6.44 |
| % Held by Insiders | 3.65% |
| % Held by Institutions | 85.43% |
| Shares Short | 9.27M |
| Short % of Float | 9.13% |
| Short % of Shares Outstanding | 6.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | September 30, 2026 |
Profitability
| Profit Margin | -47.78% |
| Operating Margin (ttm) | -226.027% |
| Gross Margin | 100.00% |
| EBITDA Margin | -29.96% |
Management Effectiveness
| Return on Assets (ttm) | -8.10% |
| Return on Equity (ttm) | -55.20% |
Income Statement
| Revenue (ttm) | 669.49M USD |
| Revenue Per Share (ttm) | 4.77 USD |
| Quarterly Revenue Growth (yoy) | 171.00% |
| Gross Profit (ttm) | 669.49M USD |
| EBITDA | -200635008 USD |
| Net Income Avi to Common (ttm) | -319955008 USD |
| Diluted EPS (ttm) | -2.28 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.6B USD |
| Total Cash Per Share (mrq) | 11.31 USD |
| Total Debt (mrq) | 1.38B USD |
| Total Debt/Equity (mrq) | 295.98 USD |
| Current Ratio (mrq) | 5.899 |
| Book Value Per Share (mrq) | 3.298 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -59055000 USD |
| Levered Free Cash Flow (ttm) | -48628124 USD |
Profile of Arrowhead Pharmaceuticals
| Country | United States |
| State | CA |
| City | Pasadena |
| Address | 177 East Colorado Boulevard |
| ZIP | 91105 |
| Phone | 626 304 3400 |
| Website | https://arrowheadpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 711 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Q&A For Arrowhead Pharmaceuticals Stock
What is a current ARWR stock price?
Arrowhead Pharmaceuticals ARWR stock price today per share is 61.48 USD.
How to purchase Arrowhead Pharmaceuticals stock?
You can buy ARWR shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arrowhead Pharmaceuticals?
The stock symbol or ticker of Arrowhead Pharmaceuticals is ARWR.
Which industry does the Arrowhead Pharmaceuticals company belong to?
The Arrowhead Pharmaceuticals industry is Biotechnology.
How many shares does Arrowhead Pharmaceuticals have in circulation?
The max supply of Arrowhead Pharmaceuticals shares is 140.86M.
What is Arrowhead Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Arrowhead Pharmaceuticals PE Ratio is now.
What was Arrowhead Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Arrowhead Pharmaceuticals EPS is -2.28 USD over the trailing 12 months.
Which sector does the Arrowhead Pharmaceuticals company belong to?
The Arrowhead Pharmaceuticals sector is Healthcare.
Arrowhead Pharmaceuticals ARWR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27538.69 USD — |
-0.22
|
6.33B USD — | 27341.31 USD — | 27547.2 USD — | — - | 6.33B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7516.65 USD — |
+0.28
|
— — | 7438.96 USD — | 7601.45 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13561.68 USD — |
-0.2
|
— — | 13462.5 USD — | 13565.81 USD — | — - | — — |
|
US Tech DM Ex Japan Large Mid Ca
NQDMXJPLMAUD
US
|
2100.38 AUD 1467.26 USD |
<0.01
|
— — | 2100.38 AUD 1467.26 USD | 2100.38 AUD 1467.26 USD | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6879.32 USD — |
+0.28
|
— — | 6808.22 USD — | 6956.93 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1295.78 USD — |
+0.26
|
— — | 1284.67 USD — | 1308.07 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
34019.06 USD — |
-0.22
|
— — | 33775.24 USD — | 34029.58 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
3916.11 USD — |
-1.47
|
— — | 3903.76 USD — | 3927.71 USD — | — - | — — |
- {{ link.label }} {{link}}
